LifeArc and Action Medical Research launch funding call for research into rare diseases in children

£1m for translational research projects focussed on children’s rare diseases

LifeArc appoints new Chief Investment Officer (CIO)

Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation

Celebrating the successes of UK translation – our 2019 annual reception

Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK

Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust

A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia

LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases

Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories

Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies

The agreement will enable LifeArc to enhance our antibody drug discovery capabilities

LifeArc invests £1.5 million in Ducentis BioTherapeutics

LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease

LifeArc monetises Keytruda® royalty interests to fund further research and investment

LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical research charities by size of investment assets

Medicines Discovery Catapult and LifeArc launch strategic R&D partnership in biomarker discovery and proteomics technology

Three-year partnership to fund clinical application of biomarker strategies to help progress novel drug candidates to clinical evaluation stage